Page 2 - PHESGO (PERTUZUMAB-TRASTUZUMAB) - Product Monograph

TABLE OF CONTENTS

1. HER2 positive disease burden 3
1.1. Epidemiology of BC 3
1.2. Disease burden of BC 3
1.3. Economic burden of BC 4

2. Unmet medical need in HER2-positive BC 5
2.1. IV HER2+ cancer care offers the results patients need - 5
but at what costs?
2.2. IV HER2+ cancer care is effective but time-consuming 6
2.3. Fixed-dose SC combination of trastuzumab and pertuzumab: 7

A new way to approach HER2+ breast cancer treatment
2.4. Liberating staff to use their time as they choose 7
2.5. Releasing resources and budget for your entire centre 8

3. Combining the antibodies you know in one faster 8
mode of administration

4. Target population for fixed-dose SC combination of 10
trastuzumab and pertuzumab

5. Proposed mechanism of action for the fixed-dose SC 10
combination of trastuzumab and pertuzumab
5.1. Specially formulated with hyaluronidase 10

5.2. How hyaluronidase is thought to work? 11

6. Fixed-dose SC combination of trastuzumab and pertuzumab: 11
Clinical efficacy and safety
6.1. FeDeriCa 11
6.2. PHranceSCa 13

7. Recommended dosing and administration for fixed-dose 15
SC combination of trastuzumab and pertuzumab
7.1. Dosing and administration for fixed-dose SC combination 15
of trastuzumab and pertuzumab
7.2. Additional dosing considerations and dose modifications 16
7.3. Preparation and storage 18
7.4. Treatment regimens for eBC and mBC, based on pertuzumab 19
studies and FeDeriCa

M-AE-00000086 2